Trelegy Ellipta vs Fasenra
A side-by-side look at two respiratory medications advertised on TV. Informational only — not medical advice.
| US Trelegy Ellipta | US Fasenra | |
|---|---|---|
| Generic name | fluticasone/umeclidinium/vilanterol | benralizumab |
| Drug class | Inhaled Corticosteroid + LAMA + LABA | IL-5 Receptor Antagonist (Biologic) |
| Treats | COPD, asthma | Severe eosinophilic asthma |
| Category | Respiratory | Respiratory |
| Manufacturer | GSK | AstraZeneca |
| Year approved | 2017 | 2017 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $200M | $80M |
| Common side effects | Thrush, Respiratory infections, Headache, Cough | Headache, Sore throat, Allergic reactions, Injection site reactions |
Trelegy Ellipta
Frequently asked questions
Is Trelegy Ellipta or Fasenra better?
Neither is universally "better." Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) and Fasenra (benralizumab) are both used for respiratory, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Trelegy Ellipta and Fasenra?
Trelegy Ellipta is a Inhaled Corticosteroid + LAMA + LABA made by GSK, while Fasenra is a IL-5 Receptor Antagonist (Biologic) made by AstraZeneca. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Trelegy Ellipta has the larger estimated TV advertising budget of the two.